Naito Akihiro, Matsumoto Akihiko, Odani Keiko, Sato Yujiro, Azuma Takeshi, Ishizawa Mitugu, Nagase Yasushi, Oshi Masaya, Homma Yukio
Department of Urology, Tokyo Metropolitan Tama Medical Center.
Nihon Hinyokika Gakkai Zasshi. 2016;107(1):34-38. doi: 10.5980/jpnjurol.107.34.
We report a 59-year-old male patient with metastatic small cell carcinoma of the bladder treated with systemic chemotherapy including an amrubicin. The patient was referred to our hospital complaining of macrohematuria. A cytoscopy revealed a non-papillary, broad-based tumor extending from the right to the posterior wall of the bladder. A computed tomography showed bilateral hydronephrosis caused by the bladder tumor and multiple metastases to the para-aortic and common iliac lymph nodes. The histopathological findings following a transurethral resection of the bladder tumor revealed a T2N3M1, LYM, stage IV small cell carcinoma. We administered two courses of systemic chemotherapy consisting of cisplatin (CDDP) plus an etoposide (VP-16), a first-line treatment usually administered to patients with small cell carcinoma of the lung. We then administered second-line chemotherapy consisting of CDDP plus an irinotecan. When the first and second-line therapies failed to halt progression of the disease, we decided to use amrubicin as the third-line therapy concomitant with radiotherapy for local control. Although the NSE (neuron-specific enolase) value decreased, the patient died 11 months after the initial examination. To our knowledge, this is the first case in which small cell carcinoma of the bladder was treated with amrubicin.
我们报告了一名59岁的男性膀胱转移性小细胞癌患者,接受了包括氨柔比星在内的全身化疗。该患者因肉眼血尿前来我院就诊。膀胱镜检查发现一个非乳头状、基底较宽的肿瘤,从膀胱右侧壁延伸至后壁。计算机断层扫描显示膀胱肿瘤导致双侧肾积水,且腹主动脉旁和髂总淋巴结有多处转移。经尿道膀胱肿瘤切除术后的组织病理学检查结果显示为T2N3M1、LYM、IV期小细胞癌。我们给予了两个疗程的全身化疗,方案为顺铂(CDDP)加依托泊苷(VP - 16),这是通常用于治疗肺小细胞癌患者的一线治疗方案。然后我们给予了二线化疗,方案为CDDP加伊立替康。当一线和二线治疗均未能阻止疾病进展时,我们决定使用氨柔比星作为三线治疗,并联合放疗进行局部控制。尽管神经元特异性烯醇化酶(NSE)值有所下降,但患者在初次检查后11个月死亡。据我们所知,这是首例使用氨柔比星治疗膀胱小细胞癌的病例。